Position of the Transparency Council – XMTVI Maxamum

At its meeting on 25 November 2024, the Transparency Council adopted position No. 133/2024 on the appropriateness of authorising the reimbursement of foodstuffs for particular nutritional uses XMTVI Maxamum for the indication: methylmalonic/propionic aciduria in paediatric patients aged 8 years and over and adults, including pregnant women, and XMTVI Maxamaid for the indication: methylmalonic/propionic aciduria in infants and young children

Publication of the position >>